Roughly one in three men taking a widely prescribed prostate drug would have shown the same urinary symptom scores if they’d been swallowing a sugar pill the whole time. A clinical trial published in JAMA Network Open in July 2026 tested it directly, handing men with enlarged prostates a placebo in place of their usual medication and tracking the results week by week.
The drug in question is tamsulosin, sold under the brand name Flomax. It belongs to a class called alpha-1 adrenergic receptor antagonists, which work by relaxing the smooth muscle tissue in the prostate and bladder neck to ease urinary flow. For many men, it provides real relief. For a substantial portion, new research suggests, it may be doing very little – and continuing to take it carries risks that grow more significant with age.
The prostate condition driving most of these prescriptions is benign prostatic hyperplasia, or BPH – a non-cancerous enlargement of the gland that sits just below the bladder. BPH is nearly universal in older men, and while it’s distinct from prostate cancer, it causes urinary symptoms that can be disruptive enough to significantly affect daily life. Alpha-1 adrenergic receptor antagonists like tamsulosin are among the most commonly prescribed treatments for these symptoms, and prescriptions often continue for years without anyone formally checking whether the drug is still working.
How Common Is BPH, and Who Gets Tamsulosin?
Tamsulosin is the most common treatment for lower urinary tract symptoms attributed to benign prostatic hyperplasia. Those symptoms include urinary urgency, nocturia (waking during the night to urinate), and a weak urinary stream – symptoms that, for some men, make a full night’s sleep or a long car trip feel like a logistical challenge.
Lower urinary tract symptoms due to BPH are common among older men, with approximately 25% of men over 40 affected. Histologic evidence of the disease – meaning the underlying tissue changes – is noted in 8% of men in their 30s, rising rapidly to over 70% after age 60. The anatomy is almost universal, even if the symptoms vary widely.
A prescription for tamsulosin often starts when symptoms are bothersome enough to bring a man to his urologist. What doesn’t follow as reliably is a formal reassessment of whether the drug is still doing its job five or ten years later. That’s the clinical gap the UCSF trial set out to quantify.
The Trial That Put Tamsulosin to the Test
Researchers conducted a double-blind randomized trial to identify which older men on tamsulosin showed little benefit and might be candidates for deprescribing. They included 31 men aged 55-80 years, with a mean age of 68.5 years, with lower urinary tract symptoms attributed to BPH, all of whom had been taking tamsulosin for at least one year.
Each patient started with placebo for one week and then completed four, two-week periods of tamsulosin or placebo in a random order, separated by a one-week washout period. This approach – known as an N-of-1 trial, where each participant serves as their own control – allowed researchers to measure individual responses rather than relying on group averages that can mask enormous variation. The crossover trial specifically aimed to evaluate whether N-of-1 deprescribing trials can identify older men who are receiving minimal benefit from tamsulosin therapy for lower urinary tract symptoms.
The researchers collected daily scores for symptoms ranging from 0 to 35 and daily scores for adverse events, classifying each man as having minimal or no response, moderate response, or strong response based on changes in symptom scores with tamsulosin versus placebo.
What the Results Actually Showed
One-third of trial participants who received tamsulosin for lower urinary tract symptoms did not experience a benefit and may warrant deprescribing. Tamsulosin treatment response proved heterogeneous, with some men experiencing little to no improvement. Specifically, of 30 participants who completed the full protocol, 11 (36.7%) had minimal or no tamsulosin effect, 11 (36.7%) had a moderate effect, 4 (13.3%) had a strong effect, and 4 (13.3%) did not tolerate the one-week placebo run-in due to worsening symptoms.
Only 13% showed a clearly strong response – the kind of benefit that most patients and physicians assume tamsulosin is providing when they don’t stop to check. More than a third were getting no more from the drug than from a sugar pill.
Response variability was wide, with individual American Urological Association Symptom Index differences ranging from -10.9 to +2.1 points, and those effects were unrelated to sequence or baseline symptom scores. A man’s starting symptom level, in other words, couldn’t predict whether tamsulosin would actually help him.
Safety signals were common, as 92.3% of participants reported at least one adverse-event day, reinforcing the need to reweigh benefit and harm over time in older adults.
Scott R. Bauer, MD, ScM, associate professor of medicine, urology, epidemiology and biostatistics at the University of California, San Francisco – whose full research profile is available at UCSF Profiles – was the study’s first author. “Tamsulosin is widely prescribed, but clinicians have little evidence to support whether it is providing meaningful benefit to an individual patient several years after treatment begins,” he said.
The Side Effects That Make Tamsulosin Unnecessary Use a Genuine Risk
Taking any medication that isn’t working is a problem on its own terms. Taking one with a meaningful side effect profile makes tamsulosin unnecessary use a matter of real safety concern, not just pharmaceutical tidiness.
Large cohort studies have reported associations between tamsulosin use and increased risk of falls due to orthostatic hypotension, particularly in elderly men. Orthostatic hypotension is a drop in blood pressure that occurs when standing up from a sitting or lying position. For a man in his 60s or 70s, a fall isn’t a minor inconvenience – it’s one of the leading causes of serious injury and hospitalization in that age group.
A study published in the BMJ found that tamsulosin resulted in a roughly doubled risk for hypotension needing hospital admission during the first eight weeks after tamsulosin initiation, with findings suggesting orthostatic hypotension is a more problematic side effect than previously thought. While that early risk is the most acute, the concern doesn’t disappear with long-term use – especially as men age, take additional medications, and become more susceptible to blood pressure fluctuations.
Tamsulosin can also cause dizziness, fatigue, and sexual dysfunction – effects that, in men who aren’t getting meaningful symptom benefit from the drug, represent unnecessary burden with no compensating upside.
The 13% Who Genuinely Need It – and How to Tell
One finding the researchers were careful not to overlook: a small but real subset of men deteriorated quickly when tamsulosin was removed. Placebo run-in intolerance occurred in 13.3% of participants, suggesting a subset of men rapidly deteriorates off therapy and may be poor candidates for deprescribing trials. These men represent the opposite end of the response spectrum – men for whom tamsulosin isn’t just helpful, it’s functionally necessary.
The study’s limitations include that researchers assessed only one treatment and washout schedule, and lacked measures of urodynamics or prostate measurements – objective tools that could help predict who is likely to be a strong responder before removing the medication. Additional limitations included the small sample size and reliance on patient-reported outcomes without uroflowmetry, prostate volume, or postvoid residual measures.
The research team called for larger studies to confirm these findings across different clinical settings and patient populations, and to identify what patient characteristics might predict whether tamsulosin is actually doing anything in a given individual. The existing evidence is strong enough, however, that it changes the conversation a physician should be having with any older man who has been on tamsulosin for years without a formal reassessment.
Deprescribing: The Practice of Stopping Medications Deliberately
The concept being tested in the UCSF trial – deliberately and systematically stopping a medication to see what happens – has a formal name: deprescribing. Deprescribing has emerged as a clinical practice to reduce polypharmacy and use of potentially inappropriate medications, serving as a mechanism for quality improvement and increased patient safety.
Polypharmacy – the simultaneous use of multiple medications – poses a significant concern for older adults due to its association with an increased risk of adverse drug events, drug interactions, and reduced adherence. The older a patient gets, the more likely they are to accumulate prescriptions from multiple physicians for multiple conditions, with each drug interacting unpredictably with the others.
Deprescribing is an important part of individualizing care for older adults. It’s an opportunity to revisit medications that may not have been reassessed in many years, and a large body of evidence suggests it is both feasible and safe.
Bauer noted that the findings suggest long-term tamsulosin therapy should be periodically reassessed because the balance between benefit and harm may change over time.
What This Means for You
If you or someone you know has been taking tamsulosin for more than a year without a formal check-in about whether it’s still working, the UCSF data make a clear case for raising that question at the next urology or primary care appointment. Ask specifically: “How do we know this medication is still providing meaningful benefit? Is there a way to test whether I still need it?”
The N-of-1 framework the UCSF researchers used isn’t yet standard clinical practice, but the principle it embodies – periodically reassessing whether a chronic medication is actually doing its job – is something any physician can apply. A brief supervised trial off tamsulosin, with close monitoring of symptom scores, can distinguish the roughly one-third of men who are getting no benefit from the smaller group who genuinely need it. For men in that first group, stopping the medication means eliminating a daily pill that raises their fall risk, contributes to dizziness, and costs money – with no compensating urinary benefit to show for it. That’s a trade worth making.
Disclaimer: The author is not a licensed medical professional. The information provided is for general informational and educational purposes only and is based on research from publicly available, reputable sources. It is not intended to constitute, and should not be relied upon as, medical advice, diagnosis, or treatment. Always consult a licensed physician or other qualified healthcare provider regarding any medical condition, symptoms, or medications. Do not disregard, avoid, or delay seeking professional medical advice or treatment because of information contained herein.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: 8 Prostate Cancer Symptoms Every Man Should Know About